Deciding Patient Factors for HCPs in the Multiple Sclerosis Marketplace
ncarol.com/10208400

RESEARCH TRIANGLE PARK, N.C. - ncarol.com -- Prescribing patterns come from a variety of factors for HCPs, but some are more important than others in the multiple sclerosis marketplace. According to newly published data by market research firm Vivisum Partners, LLC., while there may be treatments that have many points of overlap, certain distinguishing factors of brands in the MS marketplace bring to light aspects that assist HCPs in making prescribing decisions. Factors like number of failed disease modifying therapies (DMTs) and Age are "weeding out" competition in the multiple sclerosis marketplace.

For example, according to Multiple Sclerosis Competitive Landscape, neurologists view Mavenclad's patients as distinct from a treatment in the marketplace like Mayzent, whose more ideal patient has more severe symptoms and have failed 1 previous DMT. A more veteran treatment, such as Kesimpta, has a similar profile to Mayzent-apart from Age, which will be an important factor for marketing to HCPs to assist in narrowing down options available in the multiple sclerosis marketplace.

More on ncarol.com

• NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
• Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
• ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving

However, it is Ocrevus, not Mayzent that is seen as a main competitor in the multiple sclerosis marketplace. HCPs view Mayzent as a "Robin Hood,", -reflecting emotions of helpful creativity and non-conformity; "Mayzent is most competitive for patients who have moderate to severe disease, failed 1 DMT, and are younger" said Vivisum's multiple sclerosis strategist Ellen Hart.

Mavenclad differs from Mayzent patients in their disease severity and is viewed as "Nelson Mandela,", reflecting strong and inspirational leadership; Mavenclad's more ideal patient having Mild to Moderate symptoms as opposed to Mayzent's moderate to severe patients.

The market research contained in Multiple Sclerosis Competitive Landscape, found at https://vivisumpartners.com/therapeutic_areas/multiple-sclerosis/ (https://vivisumpartners.com/therapeutic_areas/multiple-sclerosis/,%20), examines the following factors that US neurologists consider when determining a brand's target patient:

• Disease Severity
• Treatment History
• Lifestyle
• Age
• Comorbidities

Multiple Sclerosis Competitive Landscape Analysis, published in October 2022 by Vivisum Partners, examines each multiple sclerosis drug's strengths and weaknesses across six key clinical attributes:

• Access
• Dosing
• Efficacy
• Safety
• Support
• Tolerability

ABOUT VIVISUM PARTNERS, LLC

More on ncarol.com

• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• Matthew Glova, CFP® of LifeTime Asset Honored in Forbes Best-In-State Wealth Advisors2025
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.